Lallemand Inc. has completed its acquisition of BIO-CAT Enzymes & Microbials, effective July 31.
This acquisition brings together complementary expertise in enzymes, microbial technologies, fermentation and life science, strengthening the companies’ collective ability to deliver innovative, science-based solutions across multiple industries, including human health.
“When my father, Ed Schuler, and I founded BIO-CAT in 1988, we built the company around family values, science, integrity and lasting relationships,” said Chris Schuler, president and CEO at BIO-CAT. “Finding a partner with shared values was just as important as finding one with complementary technologies. Lallemand's family-owned heritage, long-term vision, and commitment to its people and customers made this a natural fit, and we're excited about what we'll accomplish together.”
“The acquisition will reinforce our presence in the dietary food supplement and health ingredient markets, and increase our production footprint and capacity in the USA,” added Antoine Chagnon, CEO of Lallemand. “This, in turn, should better enable us to meet the requirements of our existing and new customers across the global animal nutrition, agriculture and food industries.”
